



BIOMAN^{4R2}



Success Story

FINANCIAL SUPPORT PROGRAM



*"The BioMan4R2 program has been a useful resource for Oniria Therapeutics, enabling a profound comprehension of the four major European markets and the UK, for Melanoma. This invaluable insight has helped our company to understand the **access to the European market** and to prepare a new funding call to achieve the next significant step for us: to know the market access strategy for the US market."*



Co-funded by
the European Union



RESILIENCE FOR REGIONAL BIOMANUFACTURING AND MEDICAL TECHNOLOGY ECOSYSTEM

*"We are trying to improve the **social and economic sustainability**, optimizing patient outcomes, and addressing potential barriers through the availability of a **treatment against cancer**, that can be taken orally. This presents an advantage that extends beyond **enhancing quality of life** since it can reduce treatment-related costs, as there is no requirement for hospitalization. By this way **Europe can strengthen its healthcare system**, enhance patient care, and effectively respond to future challenges."*

IMPACT

*"As a start-up, this type of funding is essential to move forward into the planned roadmap. It helped **Oniria** to cover the needs explained before, but also to have more information to fill the next European funding proposal to have more details about the market for specific countries and types of cancer."*



Co-funded by
the European Union